We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00261937
First Posted: December 6, 2005
Last Update Posted: February 6, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bnai Zion Medical Center
  Purpose
We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Condition Intervention Phase
Bronchiolitis Drug: Inhaled Furosemide vs Placebo (Normal Saline) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Resource links provided by NLM:


Further study details as provided by Bnai Zion Medical Center:

Primary Outcome Measures:
  • Clinical respiratory effects

Secondary Outcome Measures:
  • 1. The duration of hospitalization
  • 2. Time weaned off oxygen
  • 3. Time to full enteral feeding

Study Start Date: December 2005
Study Completion Date: April 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 0-12 months.
  • Infants who are otherwise healthy
  • Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
  • Parents signed a written informed consent.

Exclusion Criteria:

  • • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00261937


Locations
Israel
Bnai Zion Medical Center and Naharia Galilli Medical Center
Haifa, Israel, 31048
Sponsors and Collaborators
Bnai Zion Medical Center
Investigators
Principal Investigator: Amir Kugelman Bnai Zion Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00261937     History of Changes
Other Study ID Numbers: 67/05
First Submitted: December 5, 2005
First Posted: December 6, 2005
Last Update Posted: February 6, 2013
Last Verified: December 2005

Additional relevant MeSH terms:
Bronchiolitis
Bronchiolitis, Viral
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Virus Diseases
Furosemide
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action